• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Chen Shu-Chih

    7/1/24 4:00:10 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATOS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Chen Shu-Chih

    (Last) (First) (Middle)
    C/O ATOSSA THERAPEUTICS, INC.,
    107 SPRING STREET

    (Street)
    SEATTLE WA 98104

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ATOSSA THERAPEUTICS, INC. [ ATOS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/27/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $1.05 06/27/2024 A 125,000 (1) 06/27/2034 Common Stock 125,000 $0.00 125,000 D
    Explanation of Responses:
    1. The options shall vest on a quarterly basis over 12 months following June 27, 2024, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024 with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024.
    /s/ Shu-Chih Chen 07/01/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ATOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      11/12/24 1:32:30 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      11/4/24 11:27:58 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      2/9/23 11:07:47 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Atossa Therapeutics Inc.

      10-Q - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      5/13/25 8:15:19 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      5/13/25 8:05:08 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      4/7/25 4:05:13 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

      Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer. ATOS) i

      5/14/25 8:15:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

      Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

      5/13/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

      SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations. The newly granted patent includes 58 claims covering (Z)-endoxifen formulations, including various levels of purity and stability as well as methods of using those formulations. This patent provides additio

      4/30/25 8:45:06 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      3/28/25 4:00:03 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      4/11/24 4:05:09 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Financials

    Live finance-specific insights

    See more
    • Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

      Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

      5/13/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

      Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

      3/25/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

      SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024. The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-

      3/20/25 9:13:10 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Leadership Updates

    Live Leadership Updates

    See more
    • Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12

      11/12/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

      SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial

      11/5/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

      SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "We are excited to welcome Michael t

      8/20/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      3/28/25 4:00:03 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Galli Stephen J

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      7/1/24 4:00:06 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Steinhart Richard I

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      7/1/24 4:00:11 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care